MedPath

Abcentra

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:1

Trial Phases

1 Phases

Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (100.0%)

Focused Orticumab Research for Treating Inflammation in Coronary Arteries

Phase 2
Not yet recruiting
Conditions
Acute Coronary Syndromes
Coronary Arterial Disease (CAD)
Inflammation
Heart Disease
Myocardial Infarct
Atherosclerotic Coronary Vascular Disease
Interventions
Drug: Placebo
First Posted Date
2025-04-15
Last Posted Date
2025-04-17
Lead Sponsor
Abcentra
Target Recruit Count
240
Registration Number
NCT06927739

A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors

Phase 2
Completed
Conditions
Inflammation
Cardiometabolic Syndrome
Psoriasis
Coronary Artery Disease
Interventions
Drug: Placebo
First Posted Date
2021-03-02
Last Posted Date
2024-02-02
Lead Sponsor
Abcentra
Target Recruit Count
77
Registration Number
NCT04776629
Locations
🇺🇸

CCT- Research at the center for Dermatology and Plastic Surgery, Scottsdale, Arizona, United States

🇺🇸

Derm Institute & Skin Care Ctr., Inc., Santa Monica, California, United States

🇺🇸

Orange County Research Center, Tustin, California, United States

and more 10 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.